Our latest articles
Astrazeneca and Ionis’s discontinuation could herald a nervous time for others in this space.
The developer has now struck two rich deals for the antibiotics space, a field that infrequently sees big sums change hands.
Neither project is an obvious candidate for phase 3, so more mid-stage trials are planned.
When it comes to big pharma’s novel therapies, it is a case of quantity versus quality.
Paradise is now odds-on for US approval – but Medtronic’s rival device is not far behind.
The Pascal valve repair device boasts a pivotal hit and US approval, but can it compete?
Encouraging early results in hereditary angioedema join further progress in amyloidosis, but investors remain wary.
It is make or break time for the smaller group’s TL1A inhibitor PRA023.
Inhibition of Kras dominated Esmo, though probably not in the way some had hoped.
An apparent hit in Nash has more than doubled the group’s market cap. But are the data all they seem?